| P50 | author | Nadja Fratzl-Zelman | Q61822864 |
| | Barbara M Misof | Q91454622 |
| | Eleftherios P Paschalis | Q91454626 |
| | Klaus Klaushofer | Q99631558 |
| | Paul Roschger | Q114775796 |
| P2860 | cites work | Bone composition: relationship to bone fragility and antiosteoporotic drug effects | Q26863596 |
| | Apoptotic osteocytes and the control of targeted bone resorption | Q27023670 |
| | Vibrational spectroscopic imaging for the evaluation of matrix and mineral chemistry | Q28393488 |
| | Heterogeneous glycation of cancellous bone and its association with bone quality and fragility | Q28482286 |
| | Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX). | Q33478690 |
| | Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis | Q33663460 |
| | The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate | Q33700394 |
| | The effect of antiresorptives on bone quality | Q33896122 |
| | Denosumab and bisphosphonates: different mechanisms of action and effects. | Q34154083 |
| | Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review | Q34377380 |
| | Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. | Q34548650 |
| | Nanoscale heterogeneity promotes energy dissipation in bone. | Q34630299 |
| | Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis | Q34642604 |
| | Misconceptions (2): turnover is always higher in cancellous than in cortical bone | Q34674477 |
| | The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength | Q34682599 |
| | Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys | Q35109866 |
| | Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. | Q35505244 |
| | Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects | Q35566438 |
| | Bone microdamage and cell apoptosis | Q35622532 |
| | Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality | Q36633388 |
| | Fourier transform infrared spectroscopic imaging parameters describing acid phosphate substitution in biologic hydroxyapatite. | Q36780810 |
| | Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial | Q37001737 |
| | Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue | Q37137450 |
| | Spectroscopic markers of bone quality in alendronate-treated postmenopausal women | Q37149051 |
| | Finite element analysis for prediction of bone strength | Q37151666 |
| | The contribution of collagen crosslinks to bone strength | Q37404948 |
| | Bone microdamage: a clinical perspective | Q37416402 |
| | Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus | Q37598559 |
| | Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. | Q37801036 |
| | Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper | Q37997375 |
| | Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research | Q38109833 |
| | How long should women with postmenopausal osteoporosis be treated with a bisphosphonate? | Q38113740 |
| | Changes in the degree of mineralization with osteoporosis and its treatment | Q38221766 |
| | Identifying atypical femoral fractures--a retrospective review | Q38248253 |
| | Bone remodeling in response to in vivo fatigue microdamage | Q41498551 |
| | Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance | Q41726474 |
| | Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study. | Q42607777 |
| | Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial | Q42713320 |
| | Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties | Q43689965 |
| | Aging of microstructural compartments in human compact bone | Q44484948 |
| | Effect of temporal changes in bone turnover on the bone mineralization density distribution: a computer simulation study | Q44599521 |
| | Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs | Q44695650 |
| | Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. | Q44804833 |
| | Proposed pathogenesis for atypical femoral fractures: lessons from materials research. | Q45947726 |
| | The importance of intrinsic damage properties to bone fragility: a finite element study. | Q46011363 |
| | Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. | Q46023751 |
| | Time sequence of secondary mineralization and microhardness in cortical and cancellous bone from ewes. | Q46273860 |
| | In situ examination of the time-course for secondary mineralization of Haversian bone using synchrotron Fourier transform infrared microspectroscopy | Q46279213 |
| | Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume | Q46279639 |
| | Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate | Q46281049 |
| | Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women | Q46281552 |
| | Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography | Q46282127 |
| | Effects of Odanacatib on bone mineralization density distribution in thoracic spine and femora of ovariectomized adult rhesus monkeys: a quantitative backscattered electron imaging study. | Q46289368 |
| | Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. | Q46292054 |
| | Bisphosphonates do not alter the rate of secondary mineralization. | Q46293739 |
| | A theoretical analysis of long-term bisphosphonate effects on trabecular bone volume and microdamage | Q46329107 |
| | Is all cortical bone remodeling initiated by microdamage? | Q46395869 |
| | Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. | Q50514494 |
| | Incidence and bone biopsy findings of atypical femoral fractures. | Q50861958 |
| | Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization. | Q51196095 |
| | Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. | Q51565506 |
| | Effects of sodium fluoride and alendronate on the bone mineral in minipigs: a small-angle X-ray scattering and backscattered electron imaging study. | Q53961475 |
| | The true toughness of human cortical bone measured with realistically short cracks | Q59440311 |
| | Effects of alendronate and risedronate on bone material properties in actively forming trabecular bone surfaces | Q63301893 |
| | Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid | Q63301896 |
| | When the cracks begin to show | Q63761624 |
| | From brittle to ductile fracture of bone | Q63761665 |
| | Resolution-enhanced Fourier transform infrared spectroscopy study of the environment of phosphate ion in the early deposits of a solid phase of calcium phosphate in bone and enamel and their evolution with age: 2. Investigations in the nu3PO4 domain | Q67892121 |
| | Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels | Q68794203 |
| | Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition | Q70654567 |
| | Age- and sex-related changes in iliac cortical bone mass and remodeling | Q72689620 |
| | Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate | Q84707077 |
| | Differing effects of denosumab and alendronate on cortical and trabecular bone | Q86843558 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 634 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | BoneKEy reports | Q27724456 |
| P1476 | title | Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspects | |
| P478 | volume | 4 | |